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BACKGROUND: The regulatory gene pathways that accompany loss of adipose tissue in cancer cachexia are unknown and were
explored using pangenomic transcriptome profiling.
METHODS: Global gene expression profiles of abdominal subcutaneous adipose tissue were studied in gastrointestinal cancer patients
with (n¼13) or without (n¼14) cachexia.
RESULTS: Cachexia was accompanied by preferential loss of adipose tissue and decreased fat cell volume, but not number. Adipose
tissue pathways regulating energy turnover were upregulated, whereas genes in pathways related to cell and tissue structure (cellular
adhesion, extracellular matrix and actin cytoskeleton) were downregulated in cachectic patients. Transcriptional response elements
for hepatic nuclear factor-4 (HNF4) were overrepresented in the promoters of extracellular matrix and adhesion molecule genes,
and adipose HNF4 mRNA was downregulated in cachexia.
CONCLUSIONS: Cancer cachexia is characterised by preferential loss of adipose tissue; muscle mass is less affected. Loss of adipose
tissue is secondary to a decrease in adipocyte lipid content and associates with changes in the expression of genes that regulate
energy turnover, cytoskeleton and extracellular matrix, which suggest high tissue remodelling. Changes in gene expression in cachexia
are reciprocal to those observed in obesity, suggesting that regulation of fat mass at least partly corresponds to two sides of the
same coin.
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Cancer cachexia is a life-threatening condition that is typically
seen in half of untreated cancer patients (Fearon and Moses, 2002;
Deans and Wigmore, 2005). It is associated with a specific loss of
adipose tissue and skeletal muscle mass, decreased survival and
poor response to chemotherapy (Esper and Harb, 2005). Although
hyper-metabolism without a compensatory increase in food intake
is common in these patients, these factors can only partly explain
the loss of weight (Bosaeus et al, 2001).
The mechanisms behind tissue loss in cancer cachexia are
unknown, but alterations in gene expression could be involved.
Increased lipolysis and fatty acid (FA) oxidation and changes in
expression of corresponding regulatory genes have been shown in
adipose tissue of patients with cancer cachexia (Agustsson et al,
2007; Laurencikiene et al, 2008). Systemic inflammation is found in
human cachexia; however, adipose tissue levels of cytokines, and
leukocyte and macrophage markers are not altered (Ryden et al,
2008). In muscle of cancer cachexia patients increased expression
of genes regulating the ubiquitin–proteasome pathway has been
observed (Williams et al, 1999; Bossola et al, 2001).
Gene expression profiling is a useful tool to identify pivotal
regulatory pathways for altered function of adipose tissue
(Clement et al, 2004; Dahlman et al, 2006). In this study we used
global gene expression profiling to identify molecular pathways
associated with weight loss in cancer cachexia. We investigated
patients with gastrointestinal cancer who had no evidence of
gastrointestinal obstruction, and were either weight stable or
with evident cachexia. We focused on adipose tissue as preferential
wasting of this tissue is involved in the early stages of
disease (Fouladiun et al, 2005). Our primary hypothesis was that
changes in pathways involved in the regulation of energy
metabolism would accompany loss of adipose tissue in
cachexia. The change in fat mass observed with obesity is opposite
to that seen with cachexia. Our secondary hypothesis was that
this reciprocal change in fat mass is mirrored at the level of gene
expression. The latter question was investigated by comparing
global gene expression changes in the adipose tissue of
cachexia patients with our previously generated findings
examining obese and lean subjects (Dahlman et al, 2005;
Mutch et al, 2009).
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Patients
Patients scheduled for gastrointestinal cancer operation between
March 2004 and March 2008 were evaluated for the study and
patients who (a) were able to come to our clinical research
laboratory for an adipose tissue needle biopsy and relevant clinical
examinations in spite of their cancer, (b) had not received prior
anticancer treatment, (c) did not have clinical evidence of
gastrointestinal obstruction, (d) fit into the logistical scheme for
scientific studies before operation or preoperative treatment and
(e) were willing participants were included (n¼53). None of the
selected patients had jaundice. The study was approved by the
Regional Ethics committee. The investigation was explained in
detail to each patient and written informed consent was obtained.
The patients were divided into two groups on the basis of
diagnosis after surgery. The first group of patients had cancer
cachexia (n¼13), which was defined as gastrointestinal cancer
with self-reported unintentional weight loss of 45% of the
habitual weight during the previous 3 months or 410%
unintentional weight loss during the previous 6 months (Agustsson
et al, 2007). The primary location of cancer was pancreas
(n¼11), stomach (n¼1) and colon (n¼1). The second group
(n¼14) consisted of patients with gastrointestinal cancer with no
significant self-reported weight change during the last year. The
localisation of malignancy was pancreas (n¼6), oesophagus
(n¼1), stomach (n¼1), colon (n¼3), gall bladder (n¼1) and
liver (n¼2). The remaining 26 patients were excluded because
(a) although pre-diagnosed with gastrointestinal cancer they did not
have a malignancy according to final histological evaluations (n¼8)
or (b) we did not obtain adequate amounts of adipose tissue, at least
0.9g, for a complete investigation.
We used the method by Liu to determine the appropriate sample
size for microarray experiments (Liu and Hwang, 2007) (see
Supplementary Information for details).
We compared the changes in adipose tissue gene expression
associated with cachexia to changes in gene expression associated
with obesity previously reported elsewhere (Dahlman et al, 2005;
Mutch et al, 2009). One study included Affymetrix HGU95Av2
expression profiles on 17 non-obese and 20 obese healthy Swedish
women (Dahlman et al, 2005). The other study described Agilent
4 44K gene expression profiles in needle-aspirated abdominal
subcutaneous adipose tissue biopsies from nine obese and nine
lean age-matched subjects (Mutch et al, 2009). The 4 44K array
platform comprises 41000 unique 60-mer oligonucleotide human
sequences and transcripts. mRNA levels in relation to obesity were
confirmed in subcutaneous abdominal adipose tissue biopsies
from non-obese (n¼13, age 40±13 years, BMI 24±2kgm
 2) and
obese (n¼19, age 41±8 years, BMI 44±4kgm
 2) women.
To determine whether differences in gene expression detected in
the groups described in the previous paragraphs was likely to have
occurred in stroma vascular cells or in adipocytes, differences in gene
expression between these cellular fractions were examined in
subcutaneous adipose tissue in another group of overweight or obese
women (n¼9), as previously described (Clement et al, 2004). The
cDNA microarray platform used to generate this data set was
produced at Stanford University and consisted of PCR-amplified
cDNAs printed on glass slides, with 42786 spots representing 29308
UniGene clusters. These previously published microarray studies
were approved by the local Ethics Committee of the Karolinska
Institutet and in France by the CPP, Ho ˆtel-Dieu hospital (Paris).
Signed informed consents were obtained from all subjects.
Clinical examination
Patients came to the laboratory for one clinical examination
after an overnight fast. Height, weight, body composition by
bioimpedance using Quad Scan 4000 (Bodystat LTD, Isle of
Man, British Isles) and indirect calorimetry using Deltatrac
(Datex-Engstroms, Helsinki, Finland) were determined. A venous
blood sample was obtained for measuring lipids, glycerol, FAs,
albumin, sensitive CRP and IL-6, as previously described
(Agustsson et al, 2007; Ryden et al, 2008). Nutritional status was
assessed by using a standardised questionnaire for oncology
termed Subjective Global Assessment (SGA) (Ottery, 1996).
Tumour stage was classified post-operationally, as described
previously (Agustsson et al, 2007). To indirectly assess lipolytic
activity, in vivo glycerol and FA concentrations were divided by
body fat weight (Agustsson et al, 2007).
Fat biopsies
After clinical examination an abdominal subcutaneous fat sample
was obtained by needle biopsy, as previously described
(Kolaczynski et al, 1994). Tissue pieces were rapidly rinsed in
saline. A small portion was immediately used for determination of
mean fat cell volume and total number of fat cells in the body, as
previously described (Agustsson et al, 2007). Three 300-mg tissue
pieces were frozen in liquid nitrogen and kept at  701C for global
gene expression profiling, real-time quantitative PCR (RT-qPCR)
and western blotting. Tissue pieces removed and frozen in this
manner were free of damaged cells and blood (Ryden et al, 2001).
RNA preparation
WAT (300mg) was disrupted mechanically and RNA was extracted
using the Nucleospin RNA11 kit (Macherey-Nagel, Duren,
Germany). RNA samples were treated with RNase-free DNase
(Macherey-Nagel). RNA concentration and purity (in relationship
to protein) were measured spectrophotometrically using a
Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific
Sweden, Gothenburg, Sweden). Purity was measured by dividing
absorbance at 260nm (RNA) by absorbance at 280nm (protein). All
ratios were above 2.0. High-quality RNA was confirmed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Affymetrix analysis
From non-degraded high-quality total RNA we prepared and
hybridised biotinylated complementary RNA to Gene 1.0 ST
Arrays, and then washed, stained and scanned the slides using
standardised protocols (Affymetrix Inc., Santa Clara, CA, USA).
The Gene 1.0 ST Arrays measure the expression of 28869
transcripts. Subsequent data analyses were performed using the
Affymetrix GeneChip Operating Software (GCOS) version 1.4. To
allow comparisons of transcript levels between samples, all
samples were subjected to an all-probeset scaling-to-target signal
of 100. Our microarray data have been submitted to GEO in a
MIAME-compliant format (GSE20571).
Quantitative real-time PCR
One microgram of RNA was reverse transcribed using the
Omniscript RT kit (Qiagen GmbH, Hilden, Germany) and random
hexamer primers. RT-qPCR was performed using the SYBR Green-
based technology. A direct comparative method was used for data
analysis (Applied Biosystems, Foster City, CA, USA) using 18S as
internal control.
Quantification of mtDNA copy number
The ratio of mitochondrial DNA (mtDNA) to nuclear DNA reflects
the tissue concentration of mtDNA per cell and was determined by
quantitative RT-qPCR as described (Bogacka et al, 2005) (see
Supplementary Information for details).
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The protein levels of the adenine nucleotide translocator (ANT)
and cytochrome-c oxidase subunit-4 (COX-4) in adipose tissue
were measured by western blotting using antibodies from Santa
Cruz Biotechnology (Santa Cruz, CA, USA; see Supplementary
Information for details).
Statistical analysis
Differences in adipose tissue expression of individual genes
between cachectic and weight-stable cancer patients were analysed
using significance analysis of microarrays (SAM) (Tusher et al,
2001). Quantitative analysis of weight loss in SAM produced
similar results, but as the study was designed as a case–control
study we focused on the latter analysis. To evaluate the potential
functional importance of cachexia-regulated genes, we analysed
the enrichment of gene expression within predefined biological
pathways and gene ontologies (GO) in either cachectic or weight-
stable patients using the FunNet, Gene Ontology Tree Machine
(GOTM), and Gene Set Enrichment Analysis (GSEA) methods
(Ashburner et al, 2000; Zhang et al, 2004; Subramanian et al, 2005;
Prifti et al, 2008). Up- and downregulated genes were analysed
separately. The FunNet tool has been extensively described
elsewhere (Prifti et al, 2008). A false discovery rate (FDR) of 5%,
which takes into account tests for multiplicity, was used to identify
the Kyoto Encyclopedia of Genes and Genomes (KEGG) biological
pathways overrepresented in gene expression data. GOTM
compared the lists of up- and downregulated genes in cachexia
with an FDR of 5%, with a reference gene list comprising all genes
on the Gene 1.0 ST Arrays, and reported those GO that were
statistically enriched in either cachectic or weight-stable control
subjects (Zhang et al, 2004). GSEA orders measured mRNAs
according to their differential expression between two classes, for
example, cachectic vs weight-stable control patients, into a gene
list (L) (Subramanian et al, 2005). Subsequently, GSEA evaluates
whether an a priori defined set of genes shows statistically
significant, concordant differences between two biological states.
We analysed the curated functional gene sets, C2, and GOs
available in the GSEA database. We used PAINT to evaluate if
specific transcriptional regulatory elements (TREs) were over-
represented in the promoter regions of cachexia-regulated genes
using all genes on the microarray as the reference and an FDR of
20% (Vadigepalli et al, 2003). We analysed 2000 base pairs
upstream from the transcriptional start site according to Ensembl
for TREs applying a core similarity of 1.0. An unpaired Student’s
t-test was used to analyse clinical phenotypes and the expression of
individual genes. When necessary, the analysed phenotype was
log-transformed to achieve a normal distribution. SGA and tumour
stage were analysed with a Mann–Whitney test. Data are presented
as means±s.d. or means±range.
RESULTS
Clinical findings
The clinical results are shown in Table 1. BMI and body fat mass
were markedly decreased in subjects with cancer cachexia. Age,
gender distribution and lean body mass did not differ between the
two groups. The cancer cachexia group had a tumour stage of 3
(1–4) vs 4 (0–4) in the weight-stable group (P¼0.04). The
cachectic patients self-reported a marked (mean value about 10%)
decrease in their habitual weight. Cancer cachexia was accom-
panied by signs of systemic inflammation, that is, elevated CRP
and IL-6. Lipid mobilisation and oxidation were increased in
cachexia as evidenced by changes in the plasma concentrations of
glycerol and FA, and in the respiratory quotient; however, total
resting energy expenditure was similar in both the groups.
Subcutaneous fat cell volume was markedly decreased in cachexia,
but there was no change in total body fat cell number between the
groups.
Expression of matrix, cytoskeleton and metabolic gene sets
are regulated by cachexia
A total of 364 genes were downregulated and 61 genes upregulated
in the abdominal subcutaneous white adipose tissue (WAT) of
cachectic vs weight-stable patients when using an FDR of 5%
(Supplementary Table 1). Seventy-one genes were downregulated
and five genes were upregulated in the cachectic patients with an
FDR of 1% (Table 2). Table 2 also shows that cachexia-regulated
genes were fairly evenly distributed between the adipocytes
(n¼28) and the stroma vascular fraction of adipose tissue
(n¼22). We confirmed up- and downregulated expression of
genes in cachectic vs controls patients by RT-qPCR (Table 3).
We next investigated if cachexia-regulated genes belonged to
specific pathways or GOs. As minor changes in the expression of
many related genes can have a significant effect on the function of
a biological pathway, we used the differentially expressed gene list
obtained using an FDR of 5% (i.e., the 425 genes regulated by
cachexia) (Mootha et al, 2003). The FunNet analysis revealed that
genes downregulated in cachexia were overrepresented in path-
ways related to the extracellular matrix, actin cytoskeleton and
focal adhesion (Figure 1), while the pathway for FA metabolism
was overrepresented among the genes upregulated in cachexia. In
the four upregulated pathways a core group of genes appears in all
the pathways: ADH1A, ADH1B and ADH1C. The ‘fatty acid
metabolism’ pathway includes an additional gene, GCDH. Accord-
ing to GSEA, pathways related to metabolism were upregulated
among cachectic patients, for example, electron transport, FA
degradation, oxidative phosphorylation and Krebs TCA cycle
(Table 4). The pathways downregulated in cachectic patients are
more difficult to group on the basis of name; however, on closer
inspection these pathways contain many genes related to cellular
Table 1 Characteristics of study groups
Measure
Cancer –
cachexia
Cancer –
weight-
stable P-value
Gender, M/F 10/3 9/5 0.52
Age, years 65±66 5 ±8 0.75
Body mass index (BMI), kgm
 2 22.4±2.9 25.5±3.6 0.019
Body fat, % 18.5±5.8 27.4±6.6 0.001
Body fat, kg 12.7±4.7 21.0±5.0 o0.001
Lean body mass, kg 57.1±13.5 57.1±14.1 0.99
Weight loss, % of habitual weight 9.7±4.0 0.6±3.1 o0.001
P-glucose, mmoll
 1 6.6±1.6 6.4±1.7 0.71
P-triglycerides, mmoll
 1 1.1±0.4 1.4±0.5 0.059
P-cholesterol, mmoll
 1 4.6±1.3 5.0±1.2 0.41
S-albumin, gl
 1 34.6±3.9 38.2±2.7 0.012
S-CRP, mgl
 1 23.5±36.1 2.2±1.8 0.002
S-interleukin-6, mgl
 1 9.8±8.5 3.5±1.4 0.014
P-glycerol, mmol/l/kg body fat 7.0±4.3 3.4±1.6 0.01
P-fatty acids, mmol/l/kg fat 0.08±0.04 0.04±0.02 0.004
SGA score, points 8 (3–17) 2 (1–3) o0.001
Tumour stage, points 3 (1–4) 4 (0–4) 0.04
Respiratory quotient, VO2/VCO2 0.805±0.028 0.849±0.065 0.036
Resting energy expenditure, kcalday
 1 1639±304 1654±293 0.89
Fat cell volume, pico litres 331±137 504±146 0.006
Fat cell number  10
10 4.8±1.7 4.6±0.9 0.78
Abbreviations: P¼fasting plasma; S¼fasting serum; SGA¼Subjective Global
Assessment. Values are mean±s.d. or mean (range). CRP was log10 transformed
before comparison. Groups were compared by unpaired t-test, w
2-test (for gender)
or Mann–Whitney (for SGA and tumour stage).
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a
Sweden France
Gene name Gene ID Probe set Cachexia/control ratio Lean/obese ratio Adipocyte
b
Secreted frizzled-related protein-4 SFRP4 8139087 0.32 0.52 0
Sperm-associated antigen-17 SPAG17 7918973 0.35 1
RAN-binding protein-3-like RANBP3L 8111569 0.38
Atrionatriuretic peptide receptor-C NPR3 8104746 0.40 0.77 1
Secreted frizzled-related protein-2 SFRP2 8103254 0.49 0.29 0
Very-low-density lipoprotein receptor VLDLR 8154100 0.52 0.72 1
NAD(P)H dehydrogenase, quinine-1 NQO1 8002303 0.53 0.54 1
Vestigial-like-3 VGLL3 8088979 0.54 1
S100 calcium-binding protein-A4 S100A4 7920271 0.55 0.42 0
Semaphorin-3C SEMA3C 8140534 0.55 0.84 0.43 1
Hypothetical LOC401491 FLJ35024 8159850 0.56 1
Semaphorin-3B SEMA3B 8079966 0.56
Growth factor receptor-bound protein-14 GRB14 8056327 0.57 1
Adenylate cyclase-associated protein-2 CAP2 8117054 0.58 0.65 1
Follistatin-like-3 FSTL3 8023995 0.58 0.73
Placenta-specific-9 PLAC9 7928679 0.58
Cyclin-D2 CCND2 7953200 0.59 0.71 0.73 0
ADAM metallopeptidase domain-22 ADAM22 8133983 0.60 0
Leptin (obesity homologue, mouse) LEP 8135909 0.61 0.33
Peptidylglycine a-amidating monooxygenase
COOH-terminal interactor
PAMCI 7965226 0.61 1
Microtubule-associated protein-1B MAP1B 8106098 0.62
Solute carrier family-24 SLC24A3 8061227 0.62 0.55
Tripartite motif-containing-16-like TRIM16L 8005475 0.63 0
Tubulin-b-2A TUBB2A 8123644 0.63 0.72 0.37
Crystallin-aB CRYAB 7951662 0.63 0.43 1
Hexamethylene bis-acetamide inducible-1 HEXIM1 8007745 0.63 0.73 0
Nexilin (F-actin-binding protein) NEXN 7902495 0.64 1
FRAS1-related extracellular matrix-1 FREM1 8160168 0.64 0.63 1
RAB30, member RAS oncogene family RAB30 7950743 0.64 1
Slit homologue-2 SLIT2 8094301 0.64 0.70 0
Angiopoietin-1 ANGPT1 8152297 0.65 0.77
Fibroblast growth factor-1 FGF1 8114805 0.66 0.66 0.84 1
Ankyrin repeat and death domain-containing-1A ANKDD1A 7984227 0.66
Family with sequence similarity, 26, member-E FAM26E 8121601 0.67
Sulphotransferase family, cytosolic, 1A, member-2 SULT1A2 8000582 0.67 0.61 0.57
Growth differentiation factor-10 GDF10 7933372 0.67 0.62 1.35 0
WNT1-inducible signalling pathway protein-2 WISP2 8062864 0.67 0.63 0.62 0
Hypothetical protein FLJ38359 FLJ38359 8054517 0.67
Tripartite motif-containing-16 TRIM16 8012953 0.67 0.37
Pleckstrin homology domain containing, family Q m.-1 PLEKHQ1 7984217 0.68 0.52 0
Midline-1 (Opitz/BBB syndrome) MID1 8171297 0.68 0.75 1
Latent transforming growth factor-b-binding protein-2 LTBP2 7980152 0.69 0.54 1.21 0
Chromosome-1 open reading frame 198 C1orf198 7924996 0.69 0.60 1
Tuftelin-1 TUFT1 7905428 0.71 0
Spectrin, a, non-erythrocytic-1 SPTAN1 8158317 0.71 0.85 0
DIX domain containing-1 DIXDC1 7943803 0.71 1
Phosphodiesterase-4D-interacting protein PDE4DIP 7919168 0.71
Aquaporin-3 (Gill blood group) AQP3 8160670 0.71
Synaptopodin SYNPO 8109305 0.73 0.58 1
EH domain-binding protein-1 EHBP1 8042223 0.73 0.83
HtrA serine peptidase-1 HTRA1 7931097 0.74 0.76 0.37
Tumour necrosis factor receptor superfamily, m.-25 TNFRSF25 7912040 0.75 0.48
SH3 and PX domain containing-3 SH3PX3 7985016 0.76 1
GRB2-related adaptor protein-like LOC400581 8005549 0.76
Plexin-A1 PLXNA1 8082314 0.77 0
Thrombospondin, type-I, domain containing-1 THSD1 7971813 0.77
Actinin, a-1 ACTN1 7979824 0.77 0.77 1
Sine oculis-binding protein homologue SOBP 8121319 0.77
ST6 (a-N-acetyl-neuraminyl-2,3-b-galactosyl-1,3)-
N-acetylgalactosaminide a-2,6-sialyltransferase-1
ST6GALNAC1 8018774 0.77
Chromosome-14 open reading frame 4 C14orf4 7980338 0.78 0
Plasticity related gene-1 LPPR4 7903214 0.78 1.33 0
Notch homolog-3 NOTCH3 8034940 0.79 0.70 0
Opioid growth factor receptor-like-1 OGFRL1 8120602 0.79 0.62 0
Protein tyrosine phosphatase, receptor type, U PTPRU 7899562 0.79 1
Fatty acid desaturase-3 FADS3 7948630 0.79 0.52 0
Rho guanine nucleotide-exchange factor-10-like ARHGEF10L 7898483 0.82 0
Transient receptor potential cation channel TRPM4 8030251 0.83 1
Zinc finger and BTB domain containing-47 ZBTB47 8079099 0.84
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with GOTM (Supplementary Table 2). Those genes regulated by
cachexia that correspond to the following canonical pathways are
shown in Supplementary Table 3: cell adhesion, extracellular
matrix, actin cytoskeleton, mitochondrion and electron transport.
We explored potential transcriptional regulators of these
pathways. In the promoter regions of the extracellular matrix
and cell adhesion genes there was significant overrepresentation of
the TREs for Hepatic nuclear factor-4 (HNF4) (adjusted Po0.0001,
FDR 20%) (Supplementary Figure 1). The TREs for HNF4 were
present in 20 of 51 genes. On the microarrays HNF4 mRNA levels
were downregulated in the adipose tissue of cachectic vs weight-
stable patients (146 vs 166 AU, P¼0.01). No other TREs were
overrepresented when accounting for multiple testing. For actin
cytoskeleton, mitochondrion and electron transport no common
TREs were overrepresented in the promoter regions (results not
shown).
Another level of control on gene expression is mediated by
co-regulators. Peroxisome proliferator-activated receptor-g
coactivator-1a (PGC1A) stimulates the expression of genes
regulating mitochondrial energy turnover (Mootha et al, 2003).
We therefore investigated whether PGC1A could be a primary
regulator of metabolic pathways that were upregulated in cachectic
patients. We chose to focus our analysis on the cluster of 34
PGC1A-responsive OXPHOS genes (OXPHOS-CR subset) identi-
fied by Mootha et al (2003). Sixteen (64%) of the 25 PGC1A-
responsive genes that were included in our GSEA analysis were
enriched in cachectic patients. As a comparison, of all OXPHOS
genes in the MOOTHA_OXPHOS gene set 62% were enriched in
cachectic patients. On our microarrays, mean PGC1A levels in
cachectic patients were 171 AU and in controls it was 150 AU. This
difference is non-significant with t-test. Thus, there is no evidence
that cachexia-regulated OXPHOS genes are preferentially regulated
by PGC1A, but a role for this co-regulator in controlling fat loss in
cancer cachexia cannot be excluded as PGC1A is a common
regulator of OXPHOS genes.
The observed upregulation of genes related to electron transport
and mitochondria, together with previous reports that FA
oxidation is elevated in cachexia, motivated us to analyse adipose
tissue mitochondria mass (Agustsson et al, 2007). mtDNA copy
number per cell did not differ between cachectic vs weight-stable
patients (values not shown). The levels of the mitochondrial
Table 2 (Continued)
Sweden France
Gene name Gene ID Probe set Cachexia/control ratio Lean/obese ratio Adipocyte
b
Armadillo repeat containing-7 ARMC7 8009755 0.84 1.51 0
Squalene epoxidase SQLE 8148280 0.85 1
Potassium channel tetramerisation domain containing-11 KCTD11 8004360 0.85
Cytochrome-c oxidase subunit-8A COX8A 7940835 1.22 1.22 1
Branched chain aminotransferase-2 BCAT2 8038202 1.32
Alcohol dehydrogenase-1C ADH1C 8101893 1.33 1.95 2.20 1
Phosphomannomutase-1 PMM1 8076355 1.64 1.53 1
Chromosome-7 open reading frame-24 C7orf24 8138857 1.94 1
Abbreviation: WAT¼white adipose tissue.
aResults for all cohorts are based on SAM with an FDR of 1% (cachexia and Swedish obesity cohort) or 0.5% (French obesity cohort).
bGenes enriched in fat cells (1) or the stroma vascular fraction (SVF) (0) of white adipose tissue.
Table 3 Confirmation of microarray results with RT-qPCR
Array
cachexia/control
a
RT-qPCR
cachexia/control
a P-value
b
Array
lean/obese
c
RT-qPCR
lean/obese
d P-value
b Cell(1)/SVF(0)
e
Cell adhesion
ITGB5 0.76 0.70 0.00021 0.62 0.65 0.0001 0
LOXL2 0.69 0.58 0.031 0.79 0.69 0.068 1
MFAP4 0.68 0.63 0.0089 0.57 0.65 0.01 0
ACTN1 0.77 0.55 0.0014 0.77 0.81 0.02 1
ECM2 0.78 0.64 0.0031 1.04 0.37 1
DPT 0.64 0.46 0.0013 1.04 0.42 1
Extracellular matrix
LTBP2
f 0.69 0.54 0.000044 0.54 0.36 0.0003 0
FBLN1 0.69 0.60 0.0042 0.75 0.085 0
CILP 0.63 0.66 0.028 0.33 0.0031 0
Actin cytoskeleton
SPTAN1 0.71 0.64 0.0018 0.85 0.83 0.12 0
Mitochondrion
COX8a
f 1.22 1.50 0.0079 1.22 1.00 0.49 1
CYC1 1.24 1.40 0.0076 1.21 1.06 0.30 1
PC 1.45 1.90 0.00027 1.38 1.42 0.0017 1
Abbreviation: RT-qPCR¼real-time quantitative PCR.
aCachexia (n¼13), control (n¼14).
bt-test, one-sided.
cNon-obese (n¼17) and 20 obese (n¼20).
dNon-obese (n¼13)
and 20 obese (n¼19).
eGenes enriched in fat cells (1) or the stroma vascular fraction (SVF) (0) of white adipose tissue.
fSignificant difference on microarrays with FDR 1%
between cachectic and weight-stable patients. Remaining genes are significant with an FDR of 5%.
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stable patients (0.8±0.8 AU) (P¼0.03). By contrast, there was no
difference in the levels of COX4 protein between cachectic
(1.1±0.7 AU) and weight-stable patients (1.3±0.4 AU). Taken
together, there was not a consistent increase in mitochondrial
OXPHOS proteins; however, an increase in proportion to the
general increase in the mRNA levels of mitochondrial/electron
transport genes (about 30%; Supplementary Table 3) may not
easily be detected by immunoblots given the high inter-individual
variation.
Systemic inflammation is implicated in human cachexia (Ryden
et al, 2008); however, there was no evidence for enrichment of
inflammatory gene expression among cachectic patients according
to the applied microarray analyses.
Reciprocal regulation of gene expression between cachexia
and obesity
We compared the cachexia results with our own previous gene
expression profiles from the abdominal subcutaneous adipose
tissue of obese and non-obese Swedish women (Dahlman et al,
2005). Of the 425 genes that were regulated by cachexia (when
using an FDR of 5%), 262 were detected in the analysis of obese vs
lean individuals. Expression of 83 of the 262 genes was regulated
by obesity. More importantly, 82 of the 83 genes were reciprocally
regulated by cachexia and obesity and one gene was coherently
regulated by cachexia and obesity (a subset of these genes is shown
in Table 2). We also compared our results of the cachexia study
with those of a French gene expression profiling study of
abdominal subcutaneous adipose tissue from 9 obese and 9 lean
subjects (Mutch et al, 2009). Four hundred and nine of the 425
cachexia-regulated genes were present on the microarray platform
used to study obesity in the French cohort; however, only 130
genes were significantly regulated by obesity (FDR¼0.5%) in the
French cohort. Nevertheless, 105 of these 130 genes were
reciprocally regulated by cachexia and obesity. Notably, among
the reciprocally regulated genes is the low-density lipoprotein
receptor gene, which has been shown to regulate adiposity in
experimental models (Goudriaan et al, 2001; Yagyu et al, 2002).
DISCUSSION
In this study we have, for the first time, used global gene
expression profiling as a tool to unravel regulatory pathways that
associate with the wasting of tissues in cancer cachexia. Our
cachexia patients had unambiguous signs of cachexia, including
self-reported unintentional weight loss, low serum albumin and
impaired nutritional status (SGA). Furthermore, the cachectic and
control patients had similar lean body mass, which suggests that
differences adipose tissue gene expression are not secondary to
differences in lean body mass.
KEGG
Up-regulated transcripts
3-Chloroacrylic acid degradation
1- and 2-Methylnaphthalene degradation
(3/35)
(3/35)
(3/35)
(4/35)
47.6%
57.1%
66.7%
75%
75%
75%
100%
Bile acid biosynthesis
Fatty acid metabolism Focal adhesion
Regulation of actin cytoskeleton
(10/92)
(12/92)
(14/92)
100 80 40 20 0 60
Transcriptional domain coverage (%)
01 0 0 80 40 20 60
ECM-receptor interaction
Down-regulated transcripts
Figure 1 Functional profiling depicts significantly overrepresented KEGG pathways on the basis of differentially expressed genes in cachexia vs weight-
stable patients. Using the FunNet tool, functional profiling was performed using an FDR of 5%. Only genes that have at least one annotation in KEGG were
analysed. Of the 61 upregulated genes, 35 were annotated. Of the 364 downregulated genes, 92 were annotated. The number of genes associated with
each significant pathway is indicated in relation to the total number of annotated genes in our lists of differentially expressed genes. Transcriptional domain
coverage indicates the most significant biological functions that are represented among annotated genes, ranked by percentage.
Table 4 Pathways regulated by cachexia in adipose tissue according to
GSEA
Pathways
No. of
genes
Nominal
P
FDR
q-value
Enriched in cachexia
ELECTRON_TRANSPORT_CHAIN 98 0.008 0.19
STATIN_PATHWAY_PHARMGKB 18 0.002 0.15
FATTY_ACID_DEGRADATION 23 0.004 0.17
MOOTHA_VOXPHOS 77 0.025 0.14
OXIDATIVE_PHOSPHORYLATION 59 0.041 0.17
FATTY_ACID_SYNTHESIS 16 0.018 0.16
KREBS_TCA_CYCLE 31 0.012 0.16
ADIPOCYTE_PPARG_UP 16 0.021 0.14
UBIQUINONE_BIOSYNTHESIS 15 0.002 0.14
HUMAN_MITODB_6_2002 379 0.029 0.13
NADLER_OBESITY_DN 36 0.028 0.12
ALANINE_AND_ASPARTATE_
METABOLISM
21 0.022 0.12
HYPOPHYSECTOMY_RAT_UP 34 0.03 0.13
TNFALPHA_TGZ_ADIP_DN 28 0.046 0.15
CITRATE_CYCLE_TCA_CYCLE 19 0.022 0.15
TCA 15 0.004 0.14
MITOCHONDRIA 387 0.051 0.14
FATTY_ACID_METABOLISM 79 0.05 0.17
Enriched in controls
PASSERINI_EM 34 0 0.19
SCHRAETS_MLL_UP 33 0 0.17
Abbreviations: FDR¼false discovery rate; GSEA¼Gene Set Enrichment Analysis.
Shown are pathways with an FDR q-value o0.20.
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adipose tissue. First, genes in pathways regulating energy turnover
where upregulated, that is, electron transport, FA degradation,
oxidative phosphorylation and the Krebs TCA cycle. Second, and
more surprising, genes in a number of pathways related to cellular
adhesion, extracellular matrix and actin cytoskeleton were down-
regulated. The changes in the above mentioned pathways are
reciprocal to those previously associated with obesity (Dahlman
et al, 2005; Mutch et al, 2009) and similar to the changes observed
when obese subjects experienced weight reduction (Henegar et al,
2008; Kolehmainen et al, 2008). Among all cachexia-regulated
genes measured in our own previous obesity studies, the vast
majority was reciprocally regulated by obesity and cachexia.
Our findings suggest that regulation of energy turnover,
cytoskeleton and extracellular matrix may be important for loss
of adipose tissue in cancer patients. The findings for energy
turnover are consistent with observations at the whole-body level.
Cachexia patients had increased lipid oxidation and enhanced lipid
mobilisation from adipose tissue. Fat oxidation in the fat cells
could be one of several ways to rid the body of the excess FAs
generated by lipolysis. Under normal circumstances the rate of FA
oxidation is low in fat cells, but can increase under catabolic
conditions (Wang et al, 2003). The findings are opposite to those
observed in the adipose tissue of obese and type-2 diabetic subjects
(Dahlman et al, 2006; Henegar et al, 2008).
A major function of the extracellular matrix is to provide
mechanical support for the cells and all cells need a functional
cytoskeleton; however, the matrix components may also partici-
pate in a variety of signalling events. Alterations in the
extracellular matrix lead to marked metabolic dysregulation and
failure to expand adipose tissue during excess caloric intake in
rodents (Khan et al, 2009). The expression of extracellular matrix
genes in human adipose tissue is markedly modified after weight
reduction (Kolehmainen et al, 2008). In this study we found that
cachexia was associated with decreasing fat cell volume, but no
change in fat cell number, which is in line with previous results
(Agustsson et al, 2007). Thus, one possibility is that adipose tissue
adjusts its extracellular environment to adapt to the shrinking
volume of the fat cells. Such changes in fat cell volume may alter
the demand of nutrient and oxygen support by the microvascu-
lature, thereby necessitating an adaptation of the structure of the
extracellular matrix. In rodent models of cachexia, WAT is
characterised by shrunken adipocytes with dramatically reduced
cell size and dilated interstitial space (Bing et al, 2006).
Furthermore, the shrinking fat cell may have to adjust its
cytoskeleton to maintain its intracellular volume to account for
the remaining lipid droplet. TREs for HNF4 were overrepresented
in the promoter regions of the extracellular matrix and adhesion
molecule genes. HNF4 is an important regulator of adhesion
proteins (Battle et al, 2006). We observed moderately higher
mRNA levels of HNF4A in the adipose tissue of weight-stable as
compared with that in cachectic patients, which suggests that
HNF4 could be a regulator of adhesion molecule gene expression
in cachexia.
The observation that cancer cachexia-associated changes in
several gene pathways are reciprocal to obesity but similar to those
in weight reduction has several implications. First, they may relate
to regulation of fat mass, which is not specific to cachexia per se.
Second, it seems unlikely that tumour-derived factors are
responsible for the changes in the above mentioned gene pathways.
Systemic inflammation is believed to be important in cancer
cachexia (Deans and Wigmore, 2005; Durham et al, 2009). There
was no change in the expression of inflammatory genes, suggesting
that subcutaneous adipose tissue is not the source for the increased
systemic inflammatory activity observed in these cachexia patients
(Ryden et al, 2008).
In summary, loss of adipose tissue in cancer cachexia is
accompanied by marked changes in global gene expression. Most
prominent are changes in the pathways regulating energy turnover,
extracellular matrix and cytoskeleton, which could have a role in
adipose tissue wasting. The gene pathways altered in adipose tissue
are in many ways a mirror image to those observed with obesity,
but similar to those seen with intentional weight loss, suggesting
that regulation of fat mass in cachexia and obesity could, at least in
part, be two sides of the same coin.
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